Research company Peptonic Medicals' main owner Maida Vale Capital intends to exercise warrants of series TO6 to subscribe for shares for approximately SEK 2.7 million. This is stated in a press release.The subscription corresponds to around 22 percent of all outstanding TO6 warrants. According to Peptonic, the decision is "a clear signal" of the major shareholder's continued commitment and support for the company's operations and future development.The subscription period for the warrants expires on June 12.